Drugs / DW4902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07319520 | Oct 2021 → Nov 2024 | leiomyoma | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW4902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07319520 ↗ |
| Route | Oral | “administer orally once daily” NCT07319520 ↗ |